First Wave BioPharma expects to report top-line data in the first half of 2022. “We are very pleased to complete enrollment of the second part of the RESERVOIR trial and look forward to reporting top-line data in the coming months,” stated James Sapirstein, President and CEO of First Wave BioPharma. The Company’s niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV, for COVID-19 gastrointestinal infections and FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis. First Wave BioPharma is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. 14.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047540/Source: First Wave BioPharma, Inc.

Source: New York Times January 06, 2022 12:36 UTC